Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| |||
Accelrys Inc. (subsidiary of Pharmacopeia | Personal Chemistry | Software licensing agreement | Accelrys will license the use of and provide integration support for Accord for Oracle and Accord Chemistry Control (5/23) |
Amarillo Biosciences Inc. (OTC BB:AMAR) | African Health Solutions LLC* | Licensing agreement providing | African Health Solutions gains the rights in Africa (7/15) |
Aviva Biosciences | Axon Instruments | Partnership in which Axon will make an equity investment in Aviva and provide ongoing support for the development program | Axon gains an exclusive technology license agreement, obtaining Aviva's intellectual property in design and fabrication of its planar patch clamp biochips; Aviva also will be the exclusive supplier of biochips for Axon's next-generation line of high-throughput ion channel measurement systems (6/11) |
Beyond | Genstruct | Three-year collaboration to develop an advanced software environment for interpreting systems biology data | The partnership also combines Beyond Genomics' systems biology informatics technology with Genstruct's Knowledge Assembly software (6/10) |
Isogenica Ltd.* | Graseby Dynamics | Research collaboration to assess the utility of Isogenica's Covalent Display Technology | The technology will be assessed for rapidly identifying molecules that will bind with high affinity and specificity, in Graseby's detection equipment (7/10**) |
Molecular | IBM Corp. (NYSE:IBM) | Technology collaboration to develop offerings that can help researchers analyze gene and protein expressions, discover relationships among the data to diseases and predict drug responses | In addition to joint sales and marketing efforts, IBM and Molecular Mining will explore research collaborations in areas such as visualization, pattern discovery and gene expression analysis (6/10) |
Orchid | LGC Ltd.* (UK) | Nonexclusive licensing agreement for a patent titled "Genetic Assay for Cytochrome P450 2D6" | Orchid obtained rights to market cytochrome P450 2D6 testing services in North America; financial details were not disclosed (6/7) |
Prolinx Inc.* | Milian SA* (Switzerland) | Nonexclusive distribution agreement for Prolinx's RapXtract Superparamagnetic Separation Technology | Financial terms were not disclosed (6/18) |
Proteome Systems Ltd.* (Australia) | Itochu Corp.* (Japan) | Joint venture agreement to form Proteome Systems Japan | The venture will provide proteomics research in the pharmaceutical, biotechnology, cosmetics, agriculture and research industries (6/3) |
Rosetta Biosoftware | Spotfire | Three-year agreement to | The deal provides connectivity between the Rosetta Resolver system and Spotfire DecisionSite's analytic application for genomics (5/28) |
Symyx Technologies | Dow Chemical Co. (NYSE: | Multiyear extension to a research and development collaboration focusing on the discovery of catalysts to produce polyolefins | Dow will continue to fund Symyx's discovery efforts and will have exclusive rights to commercialize materials discovered within the collaboration; Symyx will receive royalties from any product sales (6/12) |
Symyx Technologies | General Electric Co. (NYSE:GE) | Three-year patent licensing agreement that allows GE to practice certain Symyx combinatorial research methodologies covered under Symyx's issued patents | The license is limited by the number of experiments, and Symyx will receive annual payments during the term of the license (5/29) |
| |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board |